Heart Failure Online 2022 On-demand
Published: 09 May 2022
-
Views:
20020
-
Likes:
7
-
Views:
20020
-
Likes:
7
-
20m 49sPart 1 | Session 1 Session 1:1 - Patient Case: The Complex Patient Andrew JS Coats, Shelley Zieroth, Carolyn Lam, Ewa Jankowska, Ileana L Piña
-
1h 3m 43sPart 1 | Session 2 Session 1.2 - Practical Theory and Hot Topics Andrew JS Coats, Shelley Zieroth, Javed Butler, Ewa Jankowska, Carolyn Lam, Ileana L Piña
-
23m 51sPart 1 | Session 3 Session 1.3 - Patient Case Revisited: Transitioning Care and Monitoring Technology Ileana L Piña, Philipp Lurz, Loreena Hill, Harriette Van Spall, Rajiv Sankaranarayanan
-
58m 23sPart 1 | Session 4 Session 1.4 - Practical Theory and Hot Topics Ileana L Piña, Philipp Lurz, Loreena Hill, Harriette Van Spall, Rajiv Sankaranarayanan
-
51m 46sPart 1 | Session 5 Symposium - The 2022 ACC Heart Failure Guidelines: What Do They Mean for Your Practice? Andrew JS Coats, Biykem Bozkurt, Mikhail Kosiborod
-
20m 17sPart 2 | Session 1 Session 2.1 - Patient Case: HF Aetiology Ileana L Piña, Shelley Zieroth, Biykem Bozkurt, Fabien Praz
-
59m 46sPart 2 | Session 2 Session 2.2 - Live MitraClip Case Ileana L Piña, Ralph Stephan von Bardeleben, Shelley Zieroth, Biykem Bozkurt, Fabien Praz
-
1h 13m 43sPart 2 | Session 3 Session 2.3 - Practical Theory and Hot Topics Shelley Zieroth, Biykem Bozkurt, Fabien Praz
-
21m 30sPart 2 | Session 4 Session 2.4 - Patient Case Revisited: Advanced HF Care Ileana L Piña, Maria Generosa Crespo-Leiro, Shelley A Hall, Alanna Morris, Massimo Piepoli, Joyce W. Wald
-
1h 44sPart 2 | Session 5 Session 2.5 - Practical Theory and Hot Topics Ileana L Piña, Maria Generosa Crespo-Leiro, Shelley A Hall, Alanna Morris, Massimo Piepoli, Joyce W. Wald
-
30m 59sPart 3 | Session 1 Session 3.1 - Patient Case: Quality of Life and Multi-disciplinary Care in HF Andrew JS Coats, Richard Hobbs, Mikhail Kosiborod, Cecilia Linde, Martin R Cowie
-
1h 20m 4sPart 3 | Session 2 Session 3.2 - Practical Theory and Hot Topics Andrew JS Coats, Richard Hobbs, Mikhail Kosiborod, Cecilia Linde, Martin R Cowie
-
40mPart 3 | Session 3 Session 3.3 - Live CRT Case Andrew JS Coats, Richard Schilling, Cecilia Linde, Martin R Cowie
Overview
Heart Failure Online (HFO) is a new innovative virtual event, that brings together a leading international faculty to create a rich, interactive experience to best inform the global heart failure community of the latest developments and advances in clinical practice.
With patient management and outcomes at its core, Course Director Prof Andrew Coats (President of the Heart Failure Association and Professor of Cardiology, University of Warwick, UK) leads an interactive programme of discussion, opinion and case studies focusing on the patient journey.
Note, the live version of this session was CME accredited; this on-demand version is not.
Key Learning Objectives
Following the activities, participants will be able to:
- Select foundational and advanced management strategies in complex patients
- Discuss the validity of using ejection fraction to determine optimal treatment strategies
- Assess the likely impact of health technology on future practice
- Identify the underlying causes of heart failure
- Select appropriate interventional and device-based treatments for treating underlying causes of heart failure
- Assess the impact of the multidisciplinary team on heart failure outcomes
- Discuss the importance of using quality of life and patient self-assessed measures relative to hard clinical end points
Target Audience
- Heart Failure Specialists
- General Cardiologists
- General Practitioners (GPs)
- Nurses, Pharmacists, and other Allied Healthcare Professionals
More from this programme
Part 1
Day One: Individualising Treatment
Part 2
Day Two: Complex Phenotypes and Advanced Treatment
Part 3
Day Three: Beyond Foundational Management
Faculty Biographies
Shelley Zieroth
Director, Heart Failure and Heart Transplant Clinics
Dr Shelley Zieroth is Professor at the College of Medicine, Max Rady Faculty of Health Sciences, University of Manitoba, as well as Director of the Heart Failure and Heart Transplant Clinics at St Boniface Hospital in Winnipeg, Canada. She is also Head of the Medical Heart Failure Program for Cardiac Sciences Manitoba.
She is involved in several heart failure clinical trials as a PI, National Lead or Executive Committee member. She is the Past President of the Canadian Heart Failure Society and Co-Chair of the Canadian Cardiovascular Society Heart Failure Guidelines. She is co-chair of Canada’s largest annual heart failure meeting, HF Update, and Past President of the Federation of Medical Women of Canada.
Dr Shelley Zieroth is an Editorial Board member of Cardiac Failure Review.
Javed Butler
Professor of Medicine
Dr Javed Butler is President, Baylor Scott and White Research Institute, Senior Vice President for the Baylor Scott and White Health and Professor of Medicine at the University of Mississippi, US. He is board certified in cardiovascular medicine and advanced heart failure and transplant medicine. His research interests focus on clinical trials in patients with heart failure.
He serves on several national committees for the American College of Cardiology, American Heart Association, National Institutes of Health, and the Heart Failure Society of America. He is the recipient of the Simon Dack Award by the American College of Cardiology as well as the Time, Feeling, and Focus Award by the American Heart Association.
Prof Butler has authored more than 900 peer-reviewed publications. He serves on the editorial board of several peer reviewed cardiovascular journals and has been cited numerous times in America’s Best Doctors list.
Carolyn Lam
Professor and Senior Consultant
Prof Carolyn Lam is a Senior Consultant at the Department of Cardiology and Director of Women's Heart Health at the National Heart Centre Singapore, having pioneered the first Women’s Heart Clinic in Singapore. Prof Lam is a world-renowned specialist in heart failure (particularly heart failure with preserved ejection fraction [HFpEF]). Her work in the PARAGON-HF and EMPEROR-Preserved trials led to the first FDA-approved treatment for HFpEF and the first robustly positive clinical outcomes trial in HFpEF to-date.